Celcuity, Inc. $CELC Stock: Pictet Asset Management Holding SA Boosts Position

Pictet Asset Management Holding SA increased its position in Celcuity, Inc. (NASDAQ:CELC) by 10,659.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 291,049 shares of the company’s stock after buying an additional 288,344 shares during the period. Pictet Asset Management Holding SA owned 0.59% of Celcuity worth $23,144,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its stake in Celcuity by 91.2% in the 1st quarter. California State Teachers Retirement System now owns 25,580 shares of the company’s stock worth $2,920,000 after acquiring an additional 12,201 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Celcuity during the 2nd quarter valued at approximately $153,928,000. E Fund Management Co. Ltd. bought a new position in shares of Celcuity during the 2nd quarter valued at approximately $4,802,000. The Manufacturers Life Insurance Company bought a new position in shares of Celcuity during the 2nd quarter valued at approximately $2,927,000. Finally, Wellington Management Group LLP grew its holdings in shares of Celcuity by 111.4% in the second quarter. Wellington Management Group LLP now owns 906,595 shares of the company’s stock valued at $94,848,000 after purchasing an additional 477,643 shares in the last quarter. 63.33% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on CELC shares. Wall Street Zen cut shares of Celcuity from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Zacks Research lowered shares of Celcuity from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 13th. Cantor Fitzgerald initiated coverage on shares of Celcuity in a research report on Thursday, October 22nd. They set an “overweight” rating and a $140.00 price objective for the company. Craig Hallum reissued a “buy” rating and issued a $178.00 price objective on shares of Celcuity in a research note on Wednesday, July 15th. Finally, Stifel Nicolaus reduced their target price on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Celcuity has an average rating of “Moderate Buy” and an average target price of $151.79.

Celcuity Stock Down 4.1%

Shares of CELC stock opened at $64.32 on Thursday. Celcuity, Inc. has a 1 year low of $53.54 and a 1 year high of $151.02. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 14.62. The stock’s 50 day simple moving average is $73.75 and its two-hundred day simple moving average is $98.74.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($1.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.51) by $0.30. Equities research analysts anticipate that Celcuity, Inc. will post -5.01 earnings per share for the current year.

Celcuity Company Profile

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.